Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
Jan 8 (Reuters) - Eli Lilly's (LLY.N), opens new tab obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the ...
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback